Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases
NCT07485166 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 810
Last updated 2026-05-08
Summary
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real-world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non Small Cell Lung Cancer
Interventions
- DRUG
-
Initiation of nivolumab
Initiation of nivolumab described in electronic health records is used as the exposure.
- DRUG
-
Initiation of docetaxel
Initiation of docetaxel described in electronic health records is used as the reference.
Sponsors & Collaborators
-
Food and Drug Administration (FDA)
collaborator FED -
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-12
- Primary Completion
- 2026-09-12
- Completion
- 2027-03-12
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
NCT06585189 ·Status: COMPLETED
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
NCT05800587 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003154 ·Status: COMPLETED ·Phase: PHASE2
-
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
NCT06607393 ·Status: COMPLETED
-
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00028028 ·Status: COMPLETED ·Phase: PHASE2
-
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00026156 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
NCT00005972 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
NCT07234877 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743 ·Status: UNKNOWN
-
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
NCT02075957 ·Status: UNKNOWN
-
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003762 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
NCT04253964 ·Status: RECRUITING ·Phase: PHASE2
-
S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00030433 ·Status: COMPLETED ·Phase: PHASE2
-
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
NCT00456261 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00278460 ·Status: COMPLETED ·Phase: PHASE2
-
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
NCT00006017 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759 ·Status: COMPLETED ·Phase: PHASE2
-
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT07405190 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
NCT01642004 ·Status: COMPLETED ·Phase: PHASE3